Evidence map›Paper›PMID 27302421›Full record

ArticleScientific reports2016

Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-κB signaling pathways.

Yingchuan Li, Zhen Zeng, Yongmei Cao, Yujing Liu, Feng Ping, Mengfan Liang, Ying Xue, Caihua Xi, Ming Zhou, Wei Jiang

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 96 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 1 synthesis or guideline pooled it, 158 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Carbon dioxide and MAPK signalling: towards therapy for inflammation.Cell communication and signaling : CCS · 2023
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Expression ofAmerican journal of respiratory cell and molecular biology · 2022
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yingchuan LiDepartment of Anesthesiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Zhen ZengDepartment of Anesthesiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Yongmei CaoDepartment of Anesthesiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Yujing LiuDepartment of Anesthesiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Feng PingDepartment of Anesthesiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Mengfan LiangDepartment of Anesthesiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Ying XueDepartment of Anesthesiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Caihua XiDepartment of Anesthesiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Ming ZhouDepartment of Anesthesiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Wei JiangDepartment of Anesthesiology, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Shanghai Sixth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute respiratory distress syndrome (ARDS) caused by severe sepsis remains a major challenge in intensive care medicine. ACE2 has been shown to protect against lung injury. However, the mechanisms of its protective effects on ARDS are largely unknown. Here, we report that ACE2 prevents LPS-induced ARDS by inhibiting MAPKs and NF-κB signaling pathway. Lentiviral packaged Ace2 cDNA or Ace2 shRNA was intratracheally administrated into the lungs of male SD rats. Two weeks after gene transfer, animals received LPS (7.5 mg/Kg) injection alone or in combination with Mas receptor antagonist A779 (10 μg/Kg) or ACE2 inhibitor MLN-4760 (1 mg/Kg) pretreatment. LPS-induced lung injury and inflammatory response were significantly prevented by ACE2 overexpression and deteriorated by Ace2 shRNA. A779 or MLN-4760 pretreatment abolished the protective effects of ACE2. Moreover, overexpression of ACE2 significantly reduced the Ang II/Ang-(1-7) ratio in BALF and up-regulated Mas mRNA expression in lung, which was reversed by A779. Importantly, the blockade of ACE2 on LPS-induced phosphorylation of ERK1/2, p38 and p50/p65 was also abolished by A779. Whereas, only the ERK1/2 inhibitor significantly attenuated lung injury in ACE2 overexpressing rats pretreated with A779. Our observation suggests that AEC2 attenuates LPS-induced ARDS via the Ang-(1-7)/Mas pathway by inhibiting ERK/NF-κB activation.

Indexed as

Acute Lung InjuryAngiotensin-Converting Enzyme 2Angiotensin IIAnimalsGene Expression Regulation, EnzymologicGene Knockdown TechniquesImidazolesLentivirusLeucineLipopolysaccharidesLungMaleMAP Kinase Signaling SystemNF-kappa BPeptidyl-Dipeptidase AProto-Oncogene Mas2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acidAce2 protein, ratAngiotensin-Converting Enzyme 2Angiotensin IIImidazolesLeucineLipopolysaccharidesNF-kappa BPeptidyl-Dipeptidase AProto-Oncogene MasProto-Oncogene ProteinsReceptors, G-Protein-Coupled

Identifiers

PMID27302421
PMCPMC4908402
OpenAlexW2424704070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.